Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro

Hiroaki Ueo, Yoshihiko Maehara, Atsushi Saito, Yoshihisa Sakaguchi, Shunji Kohnoe, Keizo Sugimachi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The chemosensitivities of 62 human colon cancer tissues. 67 rectal cancer tissues and 31 tumor-adjacent normal mucosal tissues were determined using the in vitro succinate dehydrogenase inhibition (SD1) lest. These tissues obtained at the lime of surgery were exposed to carboquone (CQ). adriamycin (ADM). mitomycin C (MMC). aclacinomycin A (ACR). cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitiv-ity was considered as positive when succinate dehydrogenase (SD) activity of the drug-treated cells decreased to below 50% of that of control cells, on day 3 of exposure. Decrease in the SD activity was noted in the colon cancer tissues, compared to the rectal cancer tissues, exposed to six antitumor drugs and in particular, to CQ (p<0.05). DDP (p<0.01) and ACR (p<0.05, one-sided paired t test). Decrease in the SD activity was noted in the tumor tissues, compared to the tumor-adjacent normal tissues, exposed to CQ. MMC and ACR (p<0.01). The sensitive rates were higher in the colon cancer tissues than the rectal cancer tissues, against all six antitumor drugs. Our findings show that the rectal cancer tissues are resistant to antitumor drugs, compared to the colon cancer tissues in vitro. When selecting antitumor drugs to treat patients with a rectal cancer, the assessment for chemosensitivity of the related tissues is crucial.

Original languageEnglish
Pages (from-to)158-161
Number of pages4
JournalOncology (Switzerland)
Volume48
Issue number2
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Rectal Neoplasms
Antineoplastic Agents
Colonic Neoplasms
Carbazilquinone
Succinate Dehydrogenase
Mitomycin
In Vitro Techniques
Aclarubicin
Neoplasms
Fluorouracil
Doxorubicin
Cisplatin
Mucous Membrane

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ueo, H., Maehara, Y., Saito, A., Sakaguchi, Y., Kohnoe, S., & Sugimachi, K. (1991). Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro. Oncology (Switzerland), 48(2), 158-161. https://doi.org/10.1159/000226917

Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro. / Ueo, Hiroaki; Maehara, Yoshihiko; Saito, Atsushi; Sakaguchi, Yoshihisa; Kohnoe, Shunji; Sugimachi, Keizo.

In: Oncology (Switzerland), Vol. 48, No. 2, 01.01.1991, p. 158-161.

Research output: Contribution to journalArticle

Ueo, H, Maehara, Y, Saito, A, Sakaguchi, Y, Kohnoe, S & Sugimachi, K 1991, 'Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro', Oncology (Switzerland), vol. 48, no. 2, pp. 158-161. https://doi.org/10.1159/000226917
Ueo, Hiroaki ; Maehara, Yoshihiko ; Saito, Atsushi ; Sakaguchi, Yoshihisa ; Kohnoe, Shunji ; Sugimachi, Keizo. / Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro. In: Oncology (Switzerland). 1991 ; Vol. 48, No. 2. pp. 158-161.
@article{4dcce66a8a9243f68acb01329ab79a09,
title = "Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro",
abstract = "The chemosensitivities of 62 human colon cancer tissues. 67 rectal cancer tissues and 31 tumor-adjacent normal mucosal tissues were determined using the in vitro succinate dehydrogenase inhibition (SD1) lest. These tissues obtained at the lime of surgery were exposed to carboquone (CQ). adriamycin (ADM). mitomycin C (MMC). aclacinomycin A (ACR). cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitiv-ity was considered as positive when succinate dehydrogenase (SD) activity of the drug-treated cells decreased to below 50{\%} of that of control cells, on day 3 of exposure. Decrease in the SD activity was noted in the colon cancer tissues, compared to the rectal cancer tissues, exposed to six antitumor drugs and in particular, to CQ (p<0.05). DDP (p<0.01) and ACR (p<0.05, one-sided paired t test). Decrease in the SD activity was noted in the tumor tissues, compared to the tumor-adjacent normal tissues, exposed to CQ. MMC and ACR (p<0.01). The sensitive rates were higher in the colon cancer tissues than the rectal cancer tissues, against all six antitumor drugs. Our findings show that the rectal cancer tissues are resistant to antitumor drugs, compared to the colon cancer tissues in vitro. When selecting antitumor drugs to treat patients with a rectal cancer, the assessment for chemosensitivity of the related tissues is crucial.",
author = "Hiroaki Ueo and Yoshihiko Maehara and Atsushi Saito and Yoshihisa Sakaguchi and Shunji Kohnoe and Keizo Sugimachi",
year = "1991",
month = "1",
day = "1",
doi = "10.1159/000226917",
language = "English",
volume = "48",
pages = "158--161",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro

AU - Ueo, Hiroaki

AU - Maehara, Yoshihiko

AU - Saito, Atsushi

AU - Sakaguchi, Yoshihisa

AU - Kohnoe, Shunji

AU - Sugimachi, Keizo

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The chemosensitivities of 62 human colon cancer tissues. 67 rectal cancer tissues and 31 tumor-adjacent normal mucosal tissues were determined using the in vitro succinate dehydrogenase inhibition (SD1) lest. These tissues obtained at the lime of surgery were exposed to carboquone (CQ). adriamycin (ADM). mitomycin C (MMC). aclacinomycin A (ACR). cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitiv-ity was considered as positive when succinate dehydrogenase (SD) activity of the drug-treated cells decreased to below 50% of that of control cells, on day 3 of exposure. Decrease in the SD activity was noted in the colon cancer tissues, compared to the rectal cancer tissues, exposed to six antitumor drugs and in particular, to CQ (p<0.05). DDP (p<0.01) and ACR (p<0.05, one-sided paired t test). Decrease in the SD activity was noted in the tumor tissues, compared to the tumor-adjacent normal tissues, exposed to CQ. MMC and ACR (p<0.01). The sensitive rates were higher in the colon cancer tissues than the rectal cancer tissues, against all six antitumor drugs. Our findings show that the rectal cancer tissues are resistant to antitumor drugs, compared to the colon cancer tissues in vitro. When selecting antitumor drugs to treat patients with a rectal cancer, the assessment for chemosensitivity of the related tissues is crucial.

AB - The chemosensitivities of 62 human colon cancer tissues. 67 rectal cancer tissues and 31 tumor-adjacent normal mucosal tissues were determined using the in vitro succinate dehydrogenase inhibition (SD1) lest. These tissues obtained at the lime of surgery were exposed to carboquone (CQ). adriamycin (ADM). mitomycin C (MMC). aclacinomycin A (ACR). cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitiv-ity was considered as positive when succinate dehydrogenase (SD) activity of the drug-treated cells decreased to below 50% of that of control cells, on day 3 of exposure. Decrease in the SD activity was noted in the colon cancer tissues, compared to the rectal cancer tissues, exposed to six antitumor drugs and in particular, to CQ (p<0.05). DDP (p<0.01) and ACR (p<0.05, one-sided paired t test). Decrease in the SD activity was noted in the tumor tissues, compared to the tumor-adjacent normal tissues, exposed to CQ. MMC and ACR (p<0.01). The sensitive rates were higher in the colon cancer tissues than the rectal cancer tissues, against all six antitumor drugs. Our findings show that the rectal cancer tissues are resistant to antitumor drugs, compared to the colon cancer tissues in vitro. When selecting antitumor drugs to treat patients with a rectal cancer, the assessment for chemosensitivity of the related tissues is crucial.

UR - http://www.scopus.com/inward/record.url?scp=0026081017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026081017&partnerID=8YFLogxK

U2 - 10.1159/000226917

DO - 10.1159/000226917

M3 - Article

C2 - 1997940

AN - SCOPUS:0026081017

VL - 48

SP - 158

EP - 161

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -